JBJulie Barsalou

Julie Barsalou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Julie Barsalou has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Case report: Success of allogeneic hematopoietic stem cell transplantation for refractory systemic-onset juvenile idiopathic arthritis

    by Camille Beaufils, Catherine Proulx, Annaliesse Blincoe, Pierre Teira, Henrique Bittencourt, Sonia Cellot, Michel Duval, Marie-Paule Morin, Jean Jacques De Bruycker, Julie Couture, et al.

    Objectives: This study reports cases of systemic-onset juvenile idiopathic arthritis (sJIA) who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) at our center and reviews published outcomes of allo-HSCT in sJIA.Methods: We present a case report of two patients with sJIA who underwent allo-HSCT at a tertiary pediatric hospital. Each patient’s disease course and allo-HSCT protocol/outcome are described. Outcomes of published cases of allo-HSCT in sJIA were compared to our experience.Results: Two patients with sJIA had allo-HSCT. Both failed multiple lines of disease-modifying anti-rheumatic drugs and experienced severe disease/treatment-related complications. Despite post-HSCT complications, both recovered without sequelae. Five years post-HSCT, patient 1 is in complete remission (CR) and is off medications. Patient 2 was in CR until 11 months post-HSCT after which he developed three disease flares. At 4 years post-HSCT he is currently in CR on Adalimumab monotherapy. Engraftment was excellent with a donor chimerism of 100% for patient 1 and 93% for patient 2. In the literature, the outcome of allo-HSCT is reported in 13 sJIA patients. When merging those with our 2 patients, 1/15 patients died and 13/14 achieved CR, of which 12 are off medications (median [range] follow-up: 2.2 [0.2–7.0] years). Extended follow-up data on 11 of the 13 reported sJIA patients showed that an additional 3 patients flared at 3, 4, and 10 years post-HSCT.Conclusion: We report two patients with severe/refractory sJIA who underwent successful allo-HSCT and achieved CR. Allo-HSCT is a potential curative option for severe/refractory sJIA. It should be considered only after failure of conventional sJIA treatments and when an HLA-matched donor is available in order to lower transplant-related mortality. The outcomes of reported sJIA patients who received allo-HSCT are encouraging but long-term follow-up data are needed to better characterized the risk–benefit ratio of this procedure.


  • High-sensitivity cardiac troponin T in infants exposed to anti-Ro antibodies

    by Julie Barsalou, Edgar Jaeggi, Lars Grosse-Wortmann, Carl A Laskin, Khosrow Adeli, Earl D Silverman

    Cardiac involvement in neonatal lupus (NLE) can present as myocarditis/endocardial fibroelastosis (EFE). It is unknown if high sensitivity troponin T (hs-cTnT) is useful in identifying subclinical myocardial inflammation in infants exposed prenatally to anti-Ro antibodies. This study reports hs-cTnT levels in infants exposed to anti-Ro antibodies with/without cardiac NLE and reports cardiac magnetic resonance imaging (CMR) findings in a subset of these children. Included were 45 consecutive infants exposed prenatally to anti-Ro antibodies with (n = 7) or without (n = 38) cardiac NLE who were seen at the SickKids NLE Clinic between 2012–2014. Hs-cTnT were measured at least once and those with values ≥ 30 ng/l were offered to undergo CMR. Descriptive statistics were performed. Of 38 infants without cardiac NLE, 25 had hs-cTnT ≥ 30 ng/l (including 1 > 113 ng/l) of whom 8 underwent a CMR (all without myocarditis/EFE). All 7 cardiac NLE children had at least one hs-cTnT ≥ 30 ng/l but only 2/7 > 113 ng/l. 4/7 infants with cardiac involvement had CMR (all without myocarditis/EFE). 6/7 cardiac NLE infants had their steroid treatment adjusted based on trend of hs-cTnT levels. Only 3/45 anti-Ro antibodies exposed infants had hs-cTnT values outside the reference range reported in healthy infants. None of 12 infants who had CMR had subclinical myocarditis/EFE. Routine measurement of hs-cTnT in every anti-Ro antibody exposed infant is not indicated. Further studies are needed to define the role of hs-cTnT as a biomarker for cardiac NLE.


  • Effect of in utero hydroxychloroquine exposure on the development of cutaneous neonatal lupus erythematosus

    by Julie Barsalou, Nathalie Costedoat-Chalumeau, Adey Berhanu, Cesar Fors-Nieves, Ummara Shah, Patrick Brown, Carl A Laskin, Nathalie Morel, Kateri Levesque, Jill P Buyon, et al.

    Objective Cutaneous neonatal lupus (cNL) occurs in possibly 5%–16% of anti-Ro±anti-La antibody–exposed infants. Data suggest in utero exposure to hydroxychloroquine (HCQ) may prevent cardiac NL. The aim was to assess whether in utero exposure to HCQ decreases the risk of cNL and/or delays onset. Methods A multicentre case–control study was performed with 122 cNL cases and 434 controls born to women with a rheumatological disease who had documentation of maternal anti-Ro±anti-La antibodies at pregnancy and confirmation of medication use and the child’s outcome. A secondary analysis was performed on 262 cNL cases, irrespective of maternal diagnosis, to determine if HCQ delayed time to cNL onset. Results Twenty (16%) cNL cases were exposed to HCQ compared with 146 (34%) controls (OR 0.4 (95% CI 0.2 to 0.6); pConclusion Exposure to HCQ was associated with a reduced risk of cNL. Among cNL cases, those exposed to HCQ tend to have later onset of rash. Both findings suggest a protective effect of HCQ on cNL.


    • 23 February 2011
      • Vol. 29  (1) , 125-30

    High prevalence of primary immune deficiencies in children with autoimmune disorders.

    by Julie Barsalou, Claire Saint-Cyr, Eric Drouin, Françoise Le Deist, Elie Haddad

    Autoimmunity is a well-recognised manifestation of primary immunodeficiency disorders. However, the prevalence of primary immunodeficiency among children with autoimmune diseases is not well characterised. The objective of this retrospective study was to describe the prevalence of primary immunodeficiency disorders in a paediatric population with autoimmune diseases. We retrospectively analysed a cohort of patients investigated for diverse autoimmune conditions from June 1st 2005 to December 31st 2006 in the Rheumatology and Immunology service of a tertiary care paediatric hospital in Canada. The clinical data of patients were reported. Independently of their baseline characteristics, patients underwent a systematic immunologic workup, which was performed before treatment initiation. Thirty-three patients were included in this study. We identified 5 patients (15%) with a primary immunodeficiency disorder: common variable immunodeficiency (n=2), combined immunodeficiency (n=1) and complement component deficiency (n=2). Four other patients (12%) displayed decreased levels of immunoglobulins, B-cell lymphopenia and/or abnormal vaccinal response but did not fulfil the criteria of a defined primary immunodeficiency disorder at the time of the study. Importantly, none of these 9 patients had a particular familial history and none had a history of recurrent infections. A significant proportion of patients presenting with an autoimmune condition have an underlying primary immunodeficiency disorder that may not be clinically obvious. Additional prospective investigations are needed to further define the role for routine immunologic testing in daily clinical rheumatologic practice.


  • High Prevalence of Primary Immune Deficiencies in Children with Autoimmune Disorders

    by Julie Barsalou, Claire Saint-Cyr, Éric Drouin, Françoise Le Deist, Elie Haddad